Ketogenic Diet Reduces Body Fat In Women With Ovarian Or Endometrial Cancer

(UAB News) Sept 18, 2018 - Women with ovarian or endometrial cancer who followed the ketogenic diet for 12 weeks lost more body fat and had lower insulin levels compared to those who followed the low-fat diet recommended by the American Cancer Society, according to a new study published by researchers at the University of Alabama at Birmingham.

read article

Huge Genetic-Screening Effort Helps Pinpoint Roots Of Breast Cancer

(Nature.com) Sept 12, 2018 - A massive study of nearly 4,000 variants in a gene associated with cancer could help to pinpoint people at risk for breast or ovarian tumours. The information is sorely needed: millions of people have had their BRCA1 gene sequenced. Some variations in the DNA sequence of BRCA1 are linked to breast and ovarian cancer; others are thought to be safe. But the effects of most variants are unknown, leaving patients and physicians alike at a loss to interpret the results. The study, published on 12 September in Nature, examined the effects of thousands of such variants on the survival of cells grown in the laboratory.

read article

What's Your Breast Cancer Risk? This Study Aims To Tell You Precisely

(NBCNews.com) Sept 12, 2018 - Breast cancer is one of the most worrisome diagnoses a woman can get, and now women know that they can get a heads-up if they have an extra-high risk by getting a genetic test. Mutations in dozens of different genes can raise the risk of breast cancer, but the two best-known risk genes are BRCA1 and BRCA2. Everyone carries these genes. When breast cancer, ovarian cancer or prostate cancer runs in a family, doctors often advise getting a test to assess whether a patient carries a risky version of one of them. Now there are home tests for common BRCA1 and BRCA2 mutations. Some clearly raise a woman's risk of cancer, and she can get more regular mammograms or, as actress Angelie Jolie opted to do, have her breasts surgically removed.

read article

Celsion Announces First Patient Randomized in the Gene-Mediated Immunotherapy (GEN-1) Study of Newly Diagnosed Stage III/IV Ovarian Cancer Patients

(Morningstar) Sept 6, 2018 - OVATION II study will evaluate initial and maintenance dosing of gen-1 on progression-free survival in a two-arm, randomized trial of up to 130 patients.

read article

Voluntis Extends Partnership with AstraZeneca in Digital Therapeutics for Oncology

(Morningstar) Aug 30, 2018 - Voluntis, a digital biotech specialized in digital therapeutics, has announced the extension of its collaboration with AstraZeneca in the field of oncology.

read article

New Developments in Ovarian Cancer Treatment Are Showing Promise

(TIME Health) Aug 28, 2018 - Cancer is never an easy foe, but some types are more stubborn than others. Ovarian cancer is one of the hardest to treat. But there are signs of progress. Several recent studies have used new combination treatment strategies, including a drug that may make chemotherapy more effective and a drug originally designed to treat breast cancer. More research is needed, but the new studies provide hope for improving outcomes for women with advanced ovarian cancer, when there was little before. On its face, ovarian cancer isn’t actually more difficult to treat than other cancers like breast, prostate or lung. It is, technically, curable — as long as it is diagnosed early enough that surgery can remove all of the growths before they spread. But because the ovaries are located deep in the reproductive tract, most people are not even aware they have cancer until the malignant cells have spread beyond the ovaries and infiltrated other tissues.

read article

No Ovarian Failure Risk After HPV Vaccine, Study Finds

(Forbes) Aug 22, 2018 - Reduced ovarian function in teen girls is not a potential effect of teen vaccination, found a new study. Researchers studied more than 200,000 adolescent girls to look for a possible link between primary ovarian insufficiency and any of the vaccines recommended for teens by the Centers for Disease Control and Prevention (CDC).

read article

Drug Combination Gives ‘Exciting’ Results In Ovarian And Lung Cancer In Early Trial

(ICR [UK]) Aug 21, 2018 - Combining a new targeted cancer drug with chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed. The combination of targeted drug vistusertib along with paclitaxel chemotherapy caused tumours of over half of patients with ovarian cancer and over a third with lung cancer to shrink, and stopped patients’ cancers from growing for nearly six months. This far exceeds what is expected with standard treatments in patients with advanced disease who have already had, and have now become resistant to, standard treatment.

read article

Experimental Drug Vistusertib Could Shrinks Tumors In 50% Of Ovarian Cancer Patients, Study Suggests

(Newsweek) Aug 21, 2018 - Scientists say they have created a new drug that can attack ovarian and lung cancers in patients for whom other treatments have failed. The U.K.-based researchers used a new drug along with chemotherapy medication known as paclitaxel on 25 women with high-grade, serous ovarian cancer, and 40 participants with squamous non-small cell lung cancer. The cancers had spread across the bodies of each participant, who did not respond to standard treatment. Over half of patients with ovarian cancer and over a third with lung cancer saw their tumors shrink, according to the study, which was published in the Annals of Oncology.

read article

U.S. FDA Grants Fast Track Designation to Aravive Biologics’ AVB-S6-500

(Dallas Business Journal) Aug 20, 2018 - Aravive Biologics, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track Designation to AVB-S6-500 as a potential treatment for platinum-resistant recurrent ovarian cancer.

read article

An Intelligent Knife Can Tell Ovarian Cancer And Healthy Tissue Apart. Could It Make Surgery Smarter?

(Cancer Research UK/Science blog) Aug 17, 2018 - Surgery is a major part of ovarian cancer treatment, but it can be a blunt tool.

read article

Memorial Sloan Kettering Researchers Build a New Model of Genetically Engineered Immune Cells That May Combat Solid Tumors in the Future

(MSK) Aug 13, 2018 - Scientists at Memorial Sloan Kettering Cancer Center (MSK) announced that they have built a new model of genetically engineered immune cells in mice that may allow them to fight solid tumors.

read press release

Iovance Biotherapeutics Announces Clinical Trial Updates with Collaborators MD Anderson and Moffitt Cancer Center

(Morningstar) Aug 16, 2018 - Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced updates from its clinical collaborations with The University of Texas MD Anderson Cancer Center and Moffitt Cancer Center.

read article

Ovarian Cancer Genetics Unravelled

(Imperial College London [UK]) Aug 13, 2018 - All patients studied with high grade serous ovarian cancer showed more than one signature, suggesting that multiple mechanisms change ovarian cancer cells during the life of these cancers. This might explain why the disease is so hard to beat with therapies targeting just a single mechanism.

read article

Cellular Escape Artists May Help Explain Why Some Women Present with Advanced Ovarian Cancer

(Brigham And Women's Hospital) Aug 13, 2018 - Exhaustive study of fallopian tubes reveals evidence of 'precursor escape' -- a novel concept in high-grade serous carcinoma.

read article

PapGene, Inc. Receives FDA Breakthrough Device Designation for Liquid Biopsy Test that Detects Multiple Cancers from a Simple Blood Draw

(PapGene) Aug 8, 2018 - PapGene, Inc., a leader in the field of liquid biopsy with a focus on the development of high-performance tests to detect cancer, announced their cancer detection test has received Breakthrough Device designation from The Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA). The PapGene test is a multi-analyte test that uses a combination of circulating tumor DNA (ctDNA) and protein biomarkers to detect the presence of cancer in average risk, asymptomatic individuals over the age of 65 years old. The FDA granted Breakthrough Designation based on the test’s ability to detect both ovarian and pancreatic cancer, advancing the FDA’s goal to help give patients timely access to medical devices that provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions by expediting their development, assessment and review. “We are excited to work with FDA to deliver a test, that if approved, will detect multiple cancers from a simple blood draw. Most cancers can be cured by surgery alone if detected in their early and localized stages. This is the first step toward our vision of making pan-cancer detection a reality for patients and dramatically improving cancer survival rates,” said Howard Kaufman, Chief Executive Officer of PapGene.

read corporate press release

FDA Grants Breakthrough Device Designation for PapGene Blood-Based Cancer Test

(GenomeWeb) Aug 8, 2018 - Startup PapGene announced today that it has received Breakthrough Device designation from the US Food and Drug Administration for its blood-based cancer diagnostic assay. The FDA granted the status based on the assay's ability to detect both ovarian and pancreatic cancer. PapGene's assay uses a combination of circulating tumor DNA and protein biomarkers to detect cancers in average-risk, asymptomatic individuals over the age of 65. The FDA instituted the Breakthrough Devices Program in 2016 as part of its "Expedited Access Pathway" (EAP) program. The process helps patients have more timely access to devices and technology that provide more effective treatment or diagnosis for life-threatening diseases that do not otherwise exist. The Breakthrough Devices Program expands on the EAP program by making future 510(k) approvals eligible as well as Premarket Approval applications and de novo device submissions.

read article (free registration required)

Clovis Oncology Announces First Patient Enrolled In The Phase 3 Athena Trial

(Clovis Oncology) Aug 8, 2018 - Clovis Oncology, Inc. announced today the randomization of the first patient in the Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca®(rucaparib), a poly (ADP ribose) polymerase inhibitor (PARP), and Bristol-Myers Squibb’s PD-1 inhibitor, OPDIVO® (nivolumab), for the treatment of advanced ovarian cancer.

read corporate press release

Moffitt Cancer Center and ITUS Corporation Request Meeting with FDA Regarding Ovarian Cancer CAR-T Therapy

(Morningstar) Aug 1, 2018 - ITUS Corporation today announced that it and its research partner, Moffitt Cancer Center, have requested a meeting with the US FDA to review the plan for advancing their CAR-T therapy for Ovarian Cancer into human clinical trials.

read article

Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Cancer

(Morningstar) July 31, 2018 - Novocure announced today that the results of its INNOVATE phase 2 pilot trial have been published in Gynecologic Oncology.

read article
Next Page